CNC

$34.98+0.22 (+0.63%)

Market OpenAs of Mar 17, 7:07 PM UTC

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$34.98
Potential Upside
5%
Whystock Fair Value$36.73
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealthcare Plans

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-28.68%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.04

Recent News

Simply Wall St.
Mar 13, 2026

Centene Confronts ACA Membership Slide And Tests AI Driven Cost Controls

Centene CEO Sarah London highlighted a sharp decline in Affordable Care Act marketplace membership at the Barclays Healthcare Conference. The company is dealing with operational pressures tied to reduced Medicaid and ACA enrollments. AI tools are becoming a key part of Centene’s discussions with hospitals over suspected improper reimbursement practices. For investors watching NYSE:CNC, these membership and enrollment pressures come on top of a weak share price backdrop. Centene closed at...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 13, 2026

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 13, 2026

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
The Wall Street Journal
Mar 12, 2026

Why Investors Aren’t Fleeing to Safe-Haven Stocks

When investors fret over geopolitical shocks, they usually rotate into safe havens such as consumer staples and healthcare. Less obviously, tech and software stocks have also advanced, while traditional safety plays such as healthcare and packaged food have sold off. By the time hostilities began, those defensive sectors were already crowded—and no longer quite as cheap.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Reuters
Mar 12, 2026

US insurers and hospitals turn to new AI for age-old battle over charges vs payments

March 12 (Reuters) - Artificial intelligence is being deployed on both sides of the tug-of-war between U. healthcare systems that want to be paid more for medical procedures and insurers who want proof the services were necessary, and experts are having a hard time predicting a winner.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.